ADHD Naturally: Supplements and Herbs for Concentration

A meta-analysis of 102 studies involving 171,756 individuals estimated the global prevalence of ADHD in children and adolescents up to 18 years old at 5.29% (Polanczyk, The American Journal of Psychiatry, 2007). Waiting lists for psychiatrists are long, so parents and adult patients seek over-the-counter support, and the supplement market responds with a list of products promising focus. This article examines these promises individually, directly in the abstracts of the studies cited by manufacturers, and provides the number of each study for independent verification. You will see where the evidence truly exists, where the study says something different from the label, where it involved completely different patients, and why none of the described preparations replace psychiatric care. You will also learn how to independently check another preparation you hear about.

KEY INFORMATION
• The global prevalence of ADHD in individuals up to 18 years old is 5.29% (Polanczyk, The American Journal of Psychiatry, 2007).
• A meta-analysis of 133 studies ranks methylphenidate first for children (Cortese, The Lancet Psychiatry, 2018).
• Omega-3 has a small but significant effect (Bloch and Qawasmi, 2011).
• Zinc improved hyperactivity but not attention deficit (Bilici, 2004).
• A review of 16 studies deemed ginkgo ineffective (Sarris, 2011).

What is ADHD and why is it treated by a psychiatrist?

ADHD is a neurodevelopmental disorder diagnosed based on DSM-5 and ICD-11 criteria, not based on an internet test or the observation of a single adult. Symptoms of inattention, hyperactivity, or impulsivity must be present before the age of 12, occur in at least two environments, and significantly hinder functioning. The diagnosis is made by a doctor.

The scale of the phenomenon is well measured. Polanczyk and colleagues reviewed 9,105 records, included 102 studies with 171,756 participants from all regions of the world, and calculated a combined prevalence of 5.29% in individuals up to 18 years old (The American Journal of Psychiatry, 2007). The authors also showed that the variability of results between countries is explained by research methodology, not geography. A newer analysis by the same team found no evidence that the number of children meeting the criteria has increased over three decades when a standardized diagnostic procedure is used.

Behind the symptoms lies biology, which is visible in imaging. A large comparative analysis showed differences in the volume of subcortical structures in individuals with ADHD compared to those without a diagnosis (Hoogman, The Lancet Psychiatry, 2017). This is important for assessing supplements: a preparation that supplements a deficiency or modulates neurotransmitter function acts at a different level than the mechanism of the disorder itself. Therefore, the first step after noticing symptoms is a visit to a specialist, not shopping.

Is ADHD really increasing?

Data does not support this. The same team that calculated the global prevalence of the disorder revisited the topic seven years later to check if the increasing number of diagnoses and prescriptions indicates a rise in actual prevalence. They updated the two most comprehensive available systematic reviews and conducted a meta-regression for the year of study (Polanczyk, International Journal of Epidemiology, 2014).

A total of 154 original studies were identified for analysis, of which 135 were included in the multivariable model. The result was twofold. First, the methodological procedures, namely the adopted diagnostic criteria, the requirement to establish functional impairment, and the source of information about symptoms, were significantly associated with the heterogeneity of results. Second, neither geographical location nor the year of the study was associated with the variability of frequency estimates.

The authors conclude that over three decades, there is no evidence of an increase in the number of children meeting ADHD criteria in the population, provided that a standardized diagnostic procedure is used. This finding should be understood precisely, as it can be misinterpreted in both directions. It does not say that diagnoses are not increasing, because they are. It states that the increase in diagnoses does not mean an increase in the disorder, but rather better detection and changes in diagnostic practice. For a parent convinced that ADHD is a trend, this is the best available data-driven answer. For someone seeking over-the-counter support, it has a different meaning: since the variability of results stems from methodology, self-diagnosis based on an internet questionnaire is precisely the kind of procedure that inflates results. A diagnosis made without an interview, without assessing functioning in two environments, and without ruling out other causes is not a diagnosis.

Does ashwagandha help with ADHD?

There is no study that has verified this. Ashwagandha, or Withania somnifera, has not been studied in ADHD in either children or adults, so any answer to this question is reasoning by analogy, not a result. This is important because in this article, every other position is assigned a study with a number of participants and duration.

What has been studied concerns a different population and a different endpoint: stress and anxiety in adults without a diagnosis of ADHD, in trials usually lasting from six to twelve weeks. Transferring this to attention deficit is a leap that the data does not justify, as anxiety and inattention are not the same symptoms, even when they co-occur.

The practical conclusion is cautious. If ashwagandha is to help, it will be at most indirectly, by reducing tension, not by improving concentration as such. Separately, it is worth remembering that it is a substance with documented cases of liver damage, so it does not belong to the category of harmless supplements.

Can a supplement replace ADHD treatment?

No, and the difference in the strength of evidence is enormous. The network meta-analysis by Cortese and colleagues included 133 studies with double-blind randomization, and the efficacy analysis at a point close to 12 weeks was based on 10,068 children and adolescents and 8,131 adults (The Lancet Psychiatry, 2018). All studied medications performed better than placebo.

The table below compares standardized mean differences for core symptoms assessed by clinicians in children and adolescents. A negative value indicates the superiority of the drug over placebo, and the greater the absolute value, the stronger the effect.

The authors' conclusion is unequivocal: after considering efficacy and tolerance, methylphenidate is the first-line medication for children and adolescents, while amphetamines are for adults. Amphetamines were found to be less tolerated than placebo in both age groups, which shows that medication selection is a physician's job, not a choice from a list. Supplements do not appear in this comparison at all, as they have not undergone studies of this caliber.

We break down the separate question about cannabidiol in ADHD in the text about CBD i ADHD, and we gather the herbs that support concentration in the supplements category.

How does the treatment of adults differ from that of children?

It differs in both the efficacy of medications and their tolerance, and primarily in who assesses the improvement. The same meta-analysis of 133 studies broke down results by age groups and by source of assessment, and only then does it become clear how fragile statements like 'stimulants simply work' can be (Cortese, The Lancet Psychiatry, 2018).

In adults, according to clinicians, amphetamines outperformed placebo with a result of -0.79 (95% CI from -0.99 to -0.58), methylphenidate -0.49 (from -0.64 to -0.35), bupropion -0.46 (from -0.85 to -0.07), and atomoxetine -0.45 (from -0.58 to -0.32). Modafinil in adults did not prove to be better than placebo. In children and adolescents, according to clinicians, all studied medications had an advantage over placebo, but when symptoms were assessed by teachers, only methylphenidate and modafinil maintained their advantage.

The other side of the balance concerns tolerance, measured by the percentage of individuals who discontinued participation due to adverse effects. Amphetamines performed worse than placebo in both age groups, guanfacine worse in children and adolescents, while atomoxetine, methylphenidate, and modafinil performed worse only in adults. The authors also noted a limitation that guides remain silent about: data were sufficient for analysis at a point close to 12 weeks, but not for 26 and 52 weeks. Thus, all this knowledge describes short-term treatment. The same limitation applies to studies on supplements, only in an even more severe form.

What did the omega-3 meta-analysis show in ADHD?

Omega-3 fatty acids have the strongest evidence base among supplements, but the effect is modest. Bloch and Qawasmi collected ten randomized, placebo-controlled studies involving a total of 699 children and demonstrated a small but statistically significant impact on ADHD symptoms (Journal of the American Academy of Child and Adolescent Psychiatry, 2011).

The most interesting result is from the additional analysis. The content of eicosapentaenoic acid in the preparation significantly correlated with its effectiveness, indicating that the proportions of acids in the product matter and that not every fish oil is the same product. The authors found no signs of publication bias or heterogeneity between studies, which strengthens the credibility of the result.

The authors' conclusions are sober. They described the efficacy of omega-3 as modest compared to available pharmacotherapy, namely psychostimulants, atomoxetine, and alpha-2 receptor agonists. They acknowledged that given the mild profile of adverse effects, it may be reasonable to supplement treatment with them or to turn to them in families that refuse other psychopharmacological options. This cautious statement should be read literally: supplementing treatment, not replacing it. The decision about a specific preparation and whether it is even needed is made by the attending physician, especially when the patient is on regular medication.

Does magnesium alleviate ADHD symptoms?

The data is encouraging, but comes from small studies from years ago, and the effect proved to depend on continued intake of the preparation. Kozielec and Starobrat-Hermelin studied 116 children aged 9 to 12 with diagnosed ADHD and found magnesium deficiency in 95% of them (Magnesium Research, 1997).

The authors measured magnesium using three methods, and the results varied significantly: deficiency was most often detected in hair, in 77.6% of subjects, less frequently in red blood cells, in 58.6%, and least frequently in serum, in 33.6%. This is a practical tip for a parent receiving a laboratory result. A result from serum alone detected deficiency the least often, so a normal value in this one measurement does not close the case.

A second study, this time French, went a step further. The Mousain-Bosc team observed 40 children with ADHD symptoms for at least eight weeks while taking magnesium with vitamin B6 (Magnesium Research, 2006). Hyperactivity, excessive emotionality, and aggressiveness decreased, while attention in school improved, alongside an increase in magnesium concentration in red blood cells. One thing that advertisements remain silent about, the authors described directly: after discontinuing administration, symptoms returned within a few weeks, and magnesium levels in red blood cells dropped again. This is an argument for physician supervision, not for purchasing the preparation on one's own.

How is iron deficiency related to ADHD?

The relationship is documented and measurable, but it concerns children with actual deficiency, not all. Konofal and colleagues compared 53 children with ADHD aged 4 to 14 years with 27 individuals from the control group. The average serum ferritin was 23 ng/ml compared to 44 ng/ml in children without a diagnosis (Archives of Pediatrics and Adolescent Medicine, 2004).

An abnormal value, that is, below 30 ng/ml, was found in 84% of children with ADHD and in 18% of individuals from the control group. Lower ferritin was associated with more severe symptoms on the Conners scale for parents and greater cognitive deficits. The authors concluded that low iron stores contribute to the disorder's picture. You can find more about the mechanism itself in the entry about how iron deficiency harms a child's learning. how iron deficiency harms a child's learning.

Four years later, the same team checked what supplementation provides. The study included 23 children without anemia, with ferritin below 30 ng/ml, assigning them to iron or placebo for twelve weeks (Pediatric Neurology, 2008). The result on the ADHD Rating Scale dropped by an average of 11.0 points in the iron group, with no change in the placebo group. Improvement on the Conners scales for parents and teachers did not reach significance. This study is very small, and the authors themselves wrote that larger trials are needed. However, the practical conclusion is clear: first, a complete blood count and ferritin ordered by a physician, and only then possible supplementation.

Does zinc improve concentration in children with ADHD?

No, and this is the most frequently misrepresented result in this area. Bilici and colleagues conducted a double-blind study with placebo on 400 patients diagnosed with ADHD according to DSM-IV, lasting twelve weeks (Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004). Zinc sulfate performed better than placebo, but not in every dimension of symptoms.

Improvement was noted in hyperactivity, impulsivity, and disturbed relationships with the environment. Zinc did not reduce attention deficit. For an article about supporting concentration, this finding is decisive, as this symptom is the one most often promised in advertisements. A full therapeutic response was recorded in 28.7% of individuals in the zinc group and in 20% on placebo, meaning there is a difference, but it is small.

The authors also indicated who showed a more pronounced effect: older patients, those with a higher body mass index, and those with low baseline zinc and free fatty acid levels. This again leads to blood testing before supplementation, not after it. Zinc was well tolerated in this study, and adverse effects were reported rarely. However, the study lasted twelve weeks and says nothing about longer-term intake, so the duration of supplementation is determined by the physician. An independent review of sixteen studies on herbal and nutritional preparations listed zinc and iron among the substances with the best evidence support in ADHD (Sarris, Complementary Therapies in Medicine, 2011).

What did the study on bacopa monnieri really show?

It showed improvement in a narrow slice of working memory in healthy adults, not ADHD treatment. Stough and colleagues recruited 107 healthy volunteers for a double-blind, placebo-controlled study. 62 individuals completed it, with 80% adherence to the protocol, and neuropsychological testing was conducted at the beginning and after 90 days (Phytotherapy Research, 2008).

The preparation improved the score in a factor called working memory, specifically the accuracy of spatial working memory. It also reduced the number of false hits in the visual information processing speed test. That’s all the abstract says. There is no mention of improvement in attention or processing speed understood generally, there are no patients with ADHD, and there are no children. The authors themselves stated that further work is needed on the effective range of doses and the timing of achieving the effect.

Sarris's review placed bacopa monnieri among the promising directions for future research in ADHD, alongside methysticin, rather than among substances with proven effects. The difference between promise and evidence is significant here. If you're interested in the plant itself outside the context of ADHD, we have described it in a separate article about the properties of bacopa monnieri. Whether bacopa makes sense alongside prescribed medication is determined by a psychiatrist, as none of the studies described investigated the combination of this plant with ADHD pharmacotherapy.

Does ginkgo biloba work in ADHD?

The evidence suggests it does not. Salehi and colleagues compared ginkgo with methylphenidate in 50 outpatient patients diagnosed with ADHD, in a randomized, double-blind, parallel-group design, over six weeks (Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010).

The difference was clear in both assessment scales. In the parent-reported scale, the score improved by an average of 6.52 points in the ginkgo group and by 15.92 points in the methylphenidate group. In the teacher-reported scale, the discrepancy was even greater: 0.84 points versus 14.04 points. Ginkgo had milder side effects, as decreased appetite, headaches, and insomnia were reported more frequently after methylphenidate, but the efficacy was incomparable.

The authors' conclusion is straightforward: administering ginkgo was less effective than methylphenidate in treating ADHD. Regardless, a review of sixteen studies on herbal preparations classified ginkgo, alongside St. John's wort, as ineffective for this indication (Sarris, Complementary Therapies in Medicine, 2011). Two sources, the same conclusion. Before adding ginkgo to your medications, consult your doctor, just as you would with any other preparation. If you're looking for an overview of the plants themselves without clinical context, we have gathered them in a post about herbs for concentration and focus.

What else did the independent review of herbal preparations reveal?

It showed that the outcome depends on the substance, not on whether the preparation is natural. Sarris and colleagues searched four scientific databases, PubMed, PsycINFO, Cochrane Library, and CINAHL, up to May 26, 2011, looking exclusively for studies with randomization and a control group. Sixteen studies met the inclusion criteria, which were then assessed using a separate quality scale (Complementary Therapies in Medicine, 2011).

The table below shows how the authors categorized the substances studied. This is a rare case of a review that does not end with a statement about the need for further research, but instead points to specific preparations on both sides of the line.

Two things in this table deserve attention. First, omega-3s were placed in the inconclusive category by Sarris, although Bloch's meta-analysis from the same year showed a statistically significant effect. The discrepancy arises from a different set of included studies and a different assessment threshold, and it speaks to how delicate this result is. Second, the last row describes hopes, not findings. A manufacturer quoting this review on the packaging of a bacopa preparation moves a statement from the 'worth investigating' column to the 'proven' column.

Do rhodiola and lion's mane have evidence in ADHD?

In ADHD, they do not have any. Both plants are sometimes sold as support for focus, and the studies cited by marketing refer to completely different populations and endpoints. It's important to separate this before spending money intended for diagnostics.

A systematic review by Hung and colleagues included eleven randomized placebo-controlled studies on Rhodiola rosea monotherapy. Six concerned physical performance, four mental performance, and two patients diagnosed with a mental disorder (Phytomedicine, 2011). The authors allow for the possibility of a beneficial effect but note the lack of independent replications of individual studies. None of them addressed ADHD.

Lion's mane has one frequently cited clinical study. Mori and colleagues administered it for sixteen weeks to thirty Japanese individuals aged 50 to 80 with mild cognitive impairment, in a double-blind placebo-controlled design, assessing the outcome using a scale based on the Hasegawa Dementia Scale (Phytotherapy Research, 2009). In the eighth, twelfth, and sixteenth weeks, the active group performed significantly better than the placebo group. Four weeks after discontinuation, the results significantly declined. This data pertains to older individuals with cognitive impairments, not to a child or adult with ADHD, and the effect depended on continued use of the preparation.

Does CBD help with ADHD?

There is no evidence that it helps. The only randomized study worth mentioning is the pilot EMA-C project: 30 adults with ADHD received a cannabinoid preparation or placebo, with cognitive performance and activity level measured by the QbTest (Cooper, European Neuropsychopharmacology, 2017).

In the intention-to-treat analysis, no difference was found. Among secondary endpoints, there was a nominal improvement in hyperactivity with impulsivity and one measure of cognitive inhibition, as well as a trend toward improvement in inattention and emotional lability. After correction for multiple testing, none of these results remained significant. In the active group, one serious adverse event in the form of muscle cramps and three mild events were reported. The authors described the result as preliminary and inconclusive.

Additionally, there is the safety assessment of cannabidiol itself. The EFSA panel on nutrition, novel foods, and food allergens stated in an update that the safety of CBD cannot be established in individuals under 25 years of age, in pregnant and breastfeeding women, and in individuals taking medications simultaneously. A pharmacologically treated ADHD patient falls into the last of these groups, and a teenager into two at once. If sleep is the issue, it makes more sense to start with sleep hygiene; we have gathered proven approaches in a post about natural ways to combat insomnia.

Which myths about diet in ADHD are worth dismissing?

The two most persistent myths have been tested in large studies, and both have been disproven. The first states that sugar exacerbates symptoms. The second, that an elimination diet based on a blood test cures ADHD. The findings have been available for years, but they rarely make it into guides.

Wolraich and colleagues conducted a meta-analysis of sixteen reports, which comprised 23 placebo-controlled studies using artificial sweeteners and blinding of children, parents, and staff (JAMA, 1995). For all fourteen assessed dimensions, the confidence interval included zero. The authors conclude that sugar does not affect children's behavior or cognitive performance, and the strong belief of parents stems from expectation and situational association.

The INCA study examined an elimination diet in 100 children aged 4 to 8 years (Pelsser, The Lancet, 2011). After five weeks of a strict diet, the difference compared to the control group on the ADHD Rating Scale was 23.7 points. In the second phase, foods with high or low levels of IgG antibodies were added to those who responded to the diet. Symptoms recurred in 19 out of 30 children, or 63%, and were independent of the IgG levels in the blood. The authors stated outright that diets based on IgG tests should be discouraged. A strict diet under supervision may show whether food matters, but a commercial intolerance test does not resolve this.

How to read research results on supplements?

It takes just five concepts to independently assess whether the statement on the label is substantiated. All of them appeared in the studies mentioned above, so they are not theories detached from practice. It's worth knowing them before spending money on a product sold to a parent of a diagnosed child.

Randomization means the random assignment of participants to groups, ensuring that both groups differ only in the substance being studied. Blinding means that neither the participant nor the evaluator knows who received the product and who received the placebo. Without these two elements, improvement may stem from mere expectation, as demonstrated by a meta-analysis on sugar, where the belief of parents proved stronger than the measured effect (Wolraich, JAMA, 1995).

The third concept is the distinction between primary and secondary endpoints. The primary endpoint is declared by the authors before the study begins and determines the outcome. In the study of cannabinoids in ADHD, the primary endpoint did not achieve significance, and improvements observed among secondary endpoints disappeared after correction for multiple testing, meaning that the more things are measured, the easier it is to get a false positive result (Cooper, European Neuropsychopharmacology, 2017). The fourth concept is the confidence interval. If it includes zero, the result is consistent with a lack of effect, and that is how all fourteen dimensions in the sugar study turned out. The fifth is the standardized mean difference, which allows for comparisons between studies using different scales; the larger the absolute value, the stronger the effect. Checking these five things takes a few minutes and saves significantly more.

How long did the studies cited by the market last?

From six weeks to three months, and in two cases, the authors checked what happens after discontinuation of the product. The table below organizes the scale and duration of the studies described in this article, making it easier to assess the weight of a single statement on the label.

The two columns should be read together. Where the last column states a negative answer, the manufacturer's promise is based on transferring results from another group of patients. This does not mean that the plant does not work for anything. It only means that this work says nothing about ADHD.

How to talk to a psychiatrist about supplements?

The simplest way is to start with a list. Write down everything you are taking along with the brand names, include blood test results if you have them, and ask directly about interactions. The doctor does not judge such questions but needs a complete picture to safely manage treatment.

Three questions are always worth asking. Could any of the supplements I am taking interact with the prescribed medication? What symptoms indicate that I should report immediately? What follow-up tests make sense in my situation? Answers to these three questions resolve more than any online comparison, as they take into account comorbid conditions and the specific supplement.

What should not be done independently? Do not discontinue medication prescribed by a psychiatrist and do not change its dosage, even if the supplement seems to be working. Do not add several new supplements at once, as then no reaction can be attributed to a cause. Do not buy products from unclear sources, as no oversight comparable to that of medications is conducted for supplements. Safe practices remain those that no one questions: regular sleep, exercise, meals at fixed times, and therapeutic work on organizing the day. They will not replace treatment but improve the conditions under which treatment works.

It is also worth preparing for an answer you do not expect. The doctor may determine that a particular supplement does not make sense in your situation and provide a reason that you won't find online, such as an interaction with a medication or a comorbid condition excluding a particular substance. This is not a refusal to talk but rather a conclusion. However, if the specialist refuses to discuss supplements at all or, conversely, proposes only products without considering treatment, it is worth seeking a second opinion. An approach that combines pharmacotherapy, therapeutic work, and correction of confirmed deficiencies is now the standard, not an extravagance.

Frequently Asked Questions

Can supplements replace ADHD medications?

No. A network meta-analysis of 133 studies with double-blind randomization identified methylphenidate as the first-line medication for children and adolescents, and amphetamines for adults (Cortese, The Lancet Psychiatry, 2018). No supplement has this level of evidence, as none have undergone studies of such scale. The decision regarding treatment and any potential supplementation is made by the treating psychiatrist.

Which supplement has the strongest evidence for ADHD?

Omega-3 fatty acids. A meta-analysis of ten randomized studies involving 699 children showed a small but statistically significant effect, and the effectiveness of the preparation correlated with the content of eicosapentaenoic acid (Bloch and Qawasmi, Journal of the American Academy of Child and Adolescent Psychiatry, 2011). The authors described this effect as modest compared to pharmacotherapy and saw it as a complementary role.

Does zinc improve concentration in ADHD?

A study involving 400 patients did not show improvement in attention deficit after zinc sulfate, although hyperactivity, impulsivity, and relationship issues improved (Bilici, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004). A full therapeutic response was noted in 28.7% of the zinc group compared to 20% on placebo, indicating a difference, but it is small.

Does ginkgo biloba affect ADHD symptoms?

Not to a comparable degree with treatment. In a randomized study of 50 children, ginkgo performed significantly worse than methylphenidate on both parent and teacher scales (Salehi, Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010). An independent review of sixteen studies deemed ginkgo ineffective for this indication (Sarris, Complementary Therapies in Medicine, 2011).

Does CBD help with ADHD?

There is no evidence for that. A pilot randomized study involving 30 adults did not achieve significance in the primary endpoint, and improvements in secondary endpoints did not survive correction for multiple testing (Cooper, European Neuropsychopharmacology, 2017). One serious adverse event in the form of muscle cramps was reported in the active group.

Does sugar exacerbate ADHD symptoms?

No. A meta-analysis of sixteen reports covering 23 studies found that sugar does not affect behavior or cognitive functions in children, and the confidence intervals for all fourteen measured dimensions included zero (Wolraich, JAMA, 1995). The authors explain parents' beliefs as stemming from expectations and associations with situations where sweets are present.

Is it worth checking the iron levels in a child with ADHD?

Yes, if ordered by a doctor. In a comparative study, ferritin levels below 30 ng/ml were found in 84% of children with ADHD compared to 18% in the control group, with average concentrations of 23 and 44 ng/ml respectively (Konofal, Archives of Pediatrics and Adolescent Medicine, 2004). Supplementation without confirmed deficiency is not justified and can be harmful.

How long does it take to see the effect of natural support?

Studies lasted from six weeks to several months, and in two cases, improvement disappeared after discontinuation of the preparation (Mousain-Bosc, Magnesium Research, 2006; Mori, Phytotherapy Research, 2009). This is the opposite of stimulant medications, whose effects are evaluated in hours. Do not shorten the observation time and do not draw conclusions after a week.

Summary

After going through the abstracts, the picture is coherent and less impressive than in advertisements. The strongest data among supplements come from omega-3 fatty acids, although the authors of the meta-analysis themselves described their effect as modest compared to pharmacotherapy. It makes sense to supplement confirmed deficiencies of iron and magnesium, but only after a blood test ordered by a doctor, not preventively.

On the other side are substances whose promises have not withstood verification. Zinc improved hyperactivity but not attention deficit. Ginkgo performed worse than the drug in direct comparison and was deemed ineffective in an independent review. Bacopa monnieri, Rhodiola rosea, and Hericium erinaceus have no studies in ADHD. CBD did not achieve significance in the only pilot study with randomization.

The practical conclusion is one. Diagnosis and treatment belong to the psychiatrist, and the role of supplements begins only where the doctor sees a place for them and ends where the promise of replacing therapy begins. No product described in this text has undergone studies that would justify such a promise.

Sources: ADHD, treatment, and micronutrients

• Polanczyk G i wsp. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. The American Journal of Psychiatry, 2007.
• Polanczyk GV i wsp. ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. International Journal of Epidemiology, 2014.
• Cortese S i wsp. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults. The Lancet Psychiatry, 2018.
• Hoogman M i wsp. Subcortical brain volume differences in participants with attention deficit hyperactivity disorder. The Lancet Psychiatry, 2017.
• Bloch MH, Qawasmi A. Omega-3 fatty acid supplementation for the treatment of children with ADHD symptomatology. Journal of the American Academy of Child and Adolescent Psychiatry, 2011.
• Kozielec T, Starobrat-Hermelin B. Assessment of magnesium levels in children with attention deficit hyperactivity disorder. Magnesium Research, 1997.
• Mousain-Bosc M i wsp. Improvement of neurobehavioral disorders in children supplemented with magnesium-vitamin B6. Magnesium Research, 2006.
• Konofal E i wsp. Iron deficiency in children with attention-deficit/hyperactivity disorder. Archives of Pediatrics and Adolescent Medicine, 2004.
• Konofal E et al. Effects of iron supplementation on attention deficit hyperactivity disorder in children. Pediatric Neurology, 2008.
• Bilici M i wsp. Double-blind, placebo-controlled study of zinc sulfate in the treatment of attention deficit hyperactivity disorder. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2004.

Sources: plants, cannabinoids, and diet

• Stough C i wsp. Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning. Phytotherapy Research, 2008.
• Salehi B et al. Ginkgo biloba for attention-deficit/hyperactivity disorder in children and adolescents. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010.
• Sarris J i wsp. Complementary medicines (herbal and nutritional products) in the treatment of Attention Deficit Hyperactivity Disorder. Complementary Therapies in Medicine, 2011.
• Hung SK, Perry R, Ernst E. The effectiveness and efficacy of Rhodiola rosea L.: a systematic review of randomized clinical trials. Phytomedicine, 2011.
• Mori K i wsp. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment. Phytotherapy Research, 2009.
• Cooper RE i wsp. Cannabinoids in attention-deficit/hyperactivity disorder: a randomised-controlled trial. European Neuropsychopharmacology, 2017.
• Wolraich ML, Wilson DB, White JW. The effect of sugar on behavior or cognition in children: a meta-analysis. JAMA, 1995.
• Pelsser LM i wsp. Effects of a restricted elimination diet on the behaviour of children with attention-deficit hyperactivity disorder (INCA study). The Lancet, 2011.
• EFSA Panel on Nutrition, Novel Foods and Food Allergens. Update of the statement on safety of cannabidiol as a novel food. EFSA Journal, 2026.

This article is for informational and educational purposes only and does not constitute medical advice. Before starting to use hemp or CBD for therapeutic purposes, consult your doctor, especially if you are taking other medications, are pregnant, or breastfeeding.

Author: Michał Waluk · Opublikowano: 2026-05-11 · Aktualizacja: 2026-08-24